DE202011100767U1 - Benzoyl peroxide 5% gel as an agent for use against rosacea - Google Patents

Benzoyl peroxide 5% gel as an agent for use against rosacea Download PDF

Info

Publication number
DE202011100767U1
DE202011100767U1 DE201120100767 DE202011100767U DE202011100767U1 DE 202011100767 U1 DE202011100767 U1 DE 202011100767U1 DE 201120100767 DE201120100767 DE 201120100767 DE 202011100767 U DE202011100767 U DE 202011100767U DE 202011100767 U1 DE202011100767 U1 DE 202011100767U1
Authority
DE
Germany
Prior art keywords
gel
benzoyl peroxide
rosacea
agent
use against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE201120100767
Other languages
German (de)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to DE201120100767 priority Critical patent/DE202011100767U1/en
Publication of DE202011100767U1 publication Critical patent/DE202011100767U1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/327—Peroxy compounds, e.g. hydroperoxides, peroxides, peroxyacids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Benzoylperoxid zur Behandlung der RosazeaBenzoyl peroxide, used to treat rosacea

Description

Die bezeichnete Dermatose Rosazea ist eine Problemkrankheit, die herkömmlich mit verschiedenen Mitteln und mit geringem Erfolg behandelt wird. Der Antragsteller setzt seit vielen Jahren Benzoylperoxid 5% Gel gegen diese Hautkrankheit ein, als alleiniges Mittel. Dieses hat sich als hocheffizient erwiesen. Für den Erfolg maßgeblich ist offenbar die vom Antragsteller stets vorgeschriebene Applikationsart. Das Gel muß mit dem Fingernagel oder mit einem Löffelstiel gezielt auf jeden Einzelknoten oder auf jede Pustel als kleines Depot aufgetragen werden. Im Falle konfluierender Knoten geschieht das gleiche in streifiger Applikation.The designated dermatosis rosacea is a problem disease that is conventionally treated by various means and with little success. The applicant has been using benzoyl peroxide 5% gel for this skin disease for many years as the sole agent. This has proven to be highly efficient. For the success is apparently the always prescribed by the applicant type of application. The gel must be applied with a fingernail or a dipper stick to each individual node or to each pustule as a small depot. In the case of confluent nodes, the same happens in streaky application.

Das Ergebnis:The result:

Innerhalb weniger Tage bilden sich die kennzeichnenden bakteriell entzündlichen Erscheinungen zurück. Die Behandlungsergebnisse sind seit Anfang dieses Jahres protokollarisch erfaßt und in vielen Fällen durch Fotos vor und nach Behandlung dokumentiert. In allen Fällen gab es keinen Therapieversager.Within a few days, the characteristic bacterial inflammatory phenomena are formed. The results of the treatment have been documented since the beginning of this year and documented in many cases by photos before and after treatment. In all cases there was no treatment failure.

Anmerkung:Annotation:

Benzoylperoxid Gel 5% wird seit Jahrzehnten als Begleitmedikation zur Behandlung der Akne eingesetzt.Benzoyl Peroxide Gel 5% has been used as an adjunctive medication for the treatment of acne for decades.

Literaturangaben:Literature:

  • 1. van Zuuren, Esther J., Gupta, Aditya K., et al. „Systematic review of rosacea treatments”, Journal of the American Academy of Dermatology; Band 56, Ausgabe 1, Januar 2007, S. 107–115 .1. Van Zuuren, Esther J., Gupta, Aditya K., et al. Systematic review of rosacea treatments, Journal of the American Academy of Dermatology; Vol. 56, Issue 1, January 2007, pp. 107-115 ,
  • 2. Wollina, Uwe, „Aktuelles zur Rosazea”, hautnah dermatologie, 26. Jahrgang, Ausgabe 6, Dezember 2010, Seiten 344–346 .Second Wollina, Uwe, "News on Rosacea", firsthand dermatology, 26th year, issue 6, December 2010, pages 344-346 ,
  • 3. Bericht „Der Tablette gehört die Zukunft”, Dermaforum-Nr. 1-Jan./Feb. 2011, S. 6 .Third Report "The tablet belongs to the future", Dermaforum no. 1-Jan./Feb. 2011, p. 6 ,
  • 4. Bericht „Ist Staphylococcus epidermitis in die Rosazea-Pathogenese involviert?”, hautnah dermatologie 1–2011, S. 40 4th Report "Is Staphylococcus epidermitis Involved in Rosacea Pathogenesis?", Dermatology 1-2011, p. 40
  • 5. Bericht „Rosacea – eine Herausforderung für den Dermatologen”, Spitzenforschung in der Dermatologie, Innovationen und Auszeichnungen 2011, Seiten 116–117 .5th Report "Rosacea - a Challenge for the Dermatologist", Top Research in Dermatology, Innovations and Awards 2011, pages 116-117 ,

Claims (1)

Benzoylperoxid zur Behandlung der RosazeaBenzoyl peroxide for the treatment of rosacea
DE201120100767 2011-05-17 2011-05-17 Benzoyl peroxide 5% gel as an agent for use against rosacea Expired - Lifetime DE202011100767U1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE201120100767 DE202011100767U1 (en) 2011-05-17 2011-05-17 Benzoyl peroxide 5% gel as an agent for use against rosacea

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE201120100767 DE202011100767U1 (en) 2011-05-17 2011-05-17 Benzoyl peroxide 5% gel as an agent for use against rosacea

Publications (1)

Publication Number Publication Date
DE202011100767U1 true DE202011100767U1 (en) 2011-12-19

Family

ID=45495323

Family Applications (1)

Application Number Title Priority Date Filing Date
DE201120100767 Expired - Lifetime DE202011100767U1 (en) 2011-05-17 2011-05-17 Benzoyl peroxide 5% gel as an agent for use against rosacea

Country Status (1)

Country Link
DE (1) DE202011100767U1 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9687465B2 (en) 2012-11-27 2017-06-27 Sol-Gel Technologies Ltd. Compositions for the treatment of rosacea
US9868103B2 (en) 2005-08-02 2018-01-16 Sol-Gel Technologies Ltd. Metal oxide coating of water insoluble ingredients
WO2020170035A3 (en) * 2019-02-19 2020-09-24 Sol-Gel Technologies Ltd. Method for treatment of rosacea including patient reported outcomes thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Bericht "Der Tablette gehört die Zukunft", Dermaforum-Nr. 1-Jan./Feb. 2011, S. 6
Bericht "Ist Staphylococcus epidermitis in die Rosazea-Pathogenese involviert?", hautnah dermatologie 1-2011, S. 40
Bericht "Rosacea - eine Herausforderung für den Dermatologen", Spitzenforschung in der Dermatologie, Innovationen und Auszeichnungen 2011, Seiten 116-117
van Zuuren, Esther J., Gupta, Aditya K., et al. "Systematic review of rosacea treatments", Journal of the American Academy of Dermatology; Band 56, Ausgabe 1, Januar 2007, S. 107-115
Wollina, Uwe, "Aktuelles zur Rosazea", hautnah dermatologie, 26. Jahrgang, Ausgabe 6, Dezember 2010, Seiten 344-346

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9868103B2 (en) 2005-08-02 2018-01-16 Sol-Gel Technologies Ltd. Metal oxide coating of water insoluble ingredients
US9687465B2 (en) 2012-11-27 2017-06-27 Sol-Gel Technologies Ltd. Compositions for the treatment of rosacea
WO2020170035A3 (en) * 2019-02-19 2020-09-24 Sol-Gel Technologies Ltd. Method for treatment of rosacea including patient reported outcomes thereof
US10933046B2 (en) 2019-02-19 2021-03-02 Sol-Gel Technologies, Ltd. Method for treatment of rosacea in patients aged 65 years and older
US10945987B2 (en) 2019-02-19 2021-03-16 Sol-Gel Technologies Ltd. Method for providing early onset of action in the treatment of rosacea
US11426378B2 (en) 2019-02-19 2022-08-30 Sol-Gel Technologies Ltd. Method for long-term treatment of rosacea
US11541026B2 (en) 2019-02-19 2023-01-03 Sol-Gel Technologies Ltd. Method for treatment of rosacea
US11628155B2 (en) 2019-02-19 2023-04-18 Sol-Gel Technologies Ltd. Method for therapeutic treatment of rosacea
US11865100B2 (en) 2019-02-19 2024-01-09 Sol-Gel Technologies Ltd. Method for treatment of rosacea in patients aged 65 years and older
US11877997B2 (en) 2019-02-19 2024-01-23 Sol-Gel Technologies Ltd. Method for providing early onset of action in the treatment of rosacea

Similar Documents

Publication Publication Date Title
DE60105035D1 (en) 1ALPHA-HYDROXY-2-METHYLENE-19-NOR-HOMOPREGNACALCIFEROL AND ITS THERAPEUTIC USE
BR112014026088A2 (en) tissue treatment product, kit, method of manufacturing a tissue treatment product, treatment method, and use of the tissue treatment product
Araviiskaia et al. Dermocosmetics: beneficial adjuncts in the treatment of acne vulgaris
ATE467614T1 (en) 2-METHYLENE-19,26,27-TRINOR-(20S)-1-ALPHA-HYDROXYVITAMIN D3 AND USES THEREOF
RU2014150505A (en) METHOD FOR IDENTIFICATION OF AHR RECEPTOR LIGANDS THAT HAVE THERAPEUTIC SEVERAL SUSPENSION ACTIVITY AND INDICATED LIGANDS
DE202011100767U1 (en) Benzoyl peroxide 5% gel as an agent for use against rosacea
CO2022013167A2 (en) Compositions and methods for treating or preventing inflammatory diseases including type I and type II diabetes mellitus and thyroid diseases
Yang et al. Clinical efficacy of herbal extracts in treatment of mild to moderate acne vulgaris: an 8-week, double-blinded, randomized, controlled trial
CY1111353T1 (en) USE OF KALALIDIS COMPOUNDS FOR PRODUCTION OF MEDICINE FOR TREATMENT OF PORCELAIN
Abate et al. Keratinocytes migration promotion, proliferation induction, and free radical injury prevention by 3-hydroxytirosol
DE602005022098D1 (en) 2-METHYLENE-18,19-DINOR-1ALFA-HYDROXY-HOMOPREGNACALCIFEROL AND ITS USES
Goswami et al. Wound healing in the golden agers: what we know and the possible way ahead
ES2554110T3 (en) Use of sulfated polysaccharides as an anti-dandruff agent
Lee et al. Review on pharmacological activities of Cinnamomum subavenium
ES2578729T3 (en) Therapeutic agent for liver related diseases
Mourelle et al. Cosmeceuticals and Thalassotherapy: Recovering the skin and well-being after cancer therapies
ATE461691T1 (en) COMPOSITION FOR COSMETIC OR PHARMACEUTICAL-DERMATOLOGICAL USE
EP2223679A3 (en) Cellular rejuvenation compounds
Bakhtiyari et al. Pharmacological effects of medicinal plants on skin.
Mutluoğlu et al. Can henna prevent ulceration in diabetic feet at high risk?
CN103494725A (en) Aloe gel for inflammation diminishing and skin care
Timmons Good research is essential in these fast-moving times
Tiwari et al. Chemo-Therapeutic management of foot abscess in female asian elephant (Elephasmaximus)
Tara et al. Comparing the Ellect nf Ozonated Olive Oil and Clotrimazole Cream for the Treatment of Vulvovaginal Candidiasis
CN105106780B (en) A kind of Traditional Chinese medicine liniment for treating skin diseases

Legal Events

Date Code Title Description
R086 Non-binding declaration of licensing interest
R207 Utility model specification

Effective date: 20120209

R156 Lapse of ip right after 3 years
R156 Lapse of ip right after 3 years

Effective date: 20141202